INCY
HealthcareIncyte
Price Chart
Market Data
Financials
XBRL · SEC EDGAR2009–2025(17yr)| Metric | FY 2009 | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025Latest | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.3M | $169.9M | $94.5M | $297.1M | $354.9M | $511.5M | $753.8M | $1.1B | $1.5B | $1.9B | $2.2B | $2.7B | $3.0B | $3.4B | $3.7B | $4.2B | $5.1B | +21.2% |
| Gross Profit | — | — | — | $296.9M | $354.3M | $508.5M | $726.8M | $1.0B | $1.5B | $1.8B | $2.0B | $2.5B | $2.8B | $3.2B | $3.4B | $3.9B | $4.8B | +21.4% |
| Gross Margin | — | — | — | 99.9% | 99.8% | 99.4% | 96.4% | 94.7% | 94.8% | 95.0% | 94.7% | 95.1% | 94.9% | 93.9% | 93.1% | 92.6% | 92.8% | +0.1pp |
| Operating Income | -$139.8M | $14.0M | -$143.2M | $1.1M | -$16.1M | -$4.8M | $50.7M | $145.0M | -$243.7M | $129.2M | $402.0M | -$263.7M | $585.8M | $579.4M | $620.5M | $61.4M | $1.5B | +2368.6% |
| Operating Margin | -1508.6% | 8.3% | -151.6% | 0.4% | -4.5% | -0.9% | 6.7% | 13.1% | -15.9% | 6.9% | 18.6% | -9.9% | 19.6% | 17.1% | 16.8% | 1.4% | 29.5% | +28.0pp |
| Net Income | -$211.9M | -$31.8M | -$186.5M | -$44.3M | -$83.1M | -$48.5M | $6.5M | $104.2M | -$313.1M | $109.5M | $446.9M | -$295.7M | $948.6M | $340.7M | $597.6M | $32.6M | $1.3B | +3845.0% |
| Net Margin | -2286.8% | -18.7% | -197.5% | -14.9% | -23.4% | -9.5% | 0.9% | 9.4% | -20.4% | 5.8% | 20.7% | -11.1% | 31.8% | 10.0% | 16.2% | 0.8% | 25.0% | +24.3pp |
| Free Cash Flow | — | — | — | — | — | — | $63.4M | $184.5M | -$204.0M | $262.7M | $632.6M | -$312.0M | $568.5M | $892.1M | $464.0M | $249.1M | $1.4B | +443.9% |
| FCF Margin | — | — | — | — | — | — | 8.4% | 16.7% | -13.3% | 14.0% | 29.3% | -11.7% | 19.0% | 26.3% | 12.6% | 5.9% | 26.3% | +20.5pp |
| EPS (Diluted) | $-2.06 | $-0.26 | $-1.47 | $-0.33 | $-0.56 | $-0.29 | $0.03 | $0.54 | $-1.53 | $0.51 | $2.05 | $-1.36 | $4.27 | $1.52 | $2.65 | $0.15 | $6.41 | +4173.3% |
1. THE BIG PICTURE
Incyte is a high-growth, high-margin biopharmaceutical specialist currently racing to diversify its portfolio before its foundational product, JAKAFI, loses patent protection in 2028. While Incyte leads its peer group in revenue growth and gross margins, its valuation remains suppressed by the market's focus on this single expiration date and the regulatory hurdles facing its next generation of treatments (10-K Item 1A; Peer Benchmarking).
2. WHERE THE RISKS HIT HARDEST
Incyte’s core strength in "proprietary therapeutics" is directly threatened by generic manufacturers who have filed Abbreviated New Drug Applications (ANDAs) to challenge patents for JAKAFI and OPZELURA (10-K Item 1; Risks). This legal pressure targets the very products Incyte relies on for its 92.9% gross margins. Furthermore, the strategic priority of transitioning patients to JAKAFI XR—a move intended to extend the franchise's lifecycle—hit a significant hurdle when the FDA issued a Complete Response Letter, delaying a key component of Incyte's post-2028 defense strategy (10-K Item 1; 8-K).
3. WHAT THE NUMBERS SAY TOGETHER
The financial data reveals a company with elite top-line efficiency that has yet to translate that success into industry-leading cash flow or shareholder returns. Incyte maintains the highest gross margin in its peer group at 92.9%, yet it ranks 5th of 6 in FCFFCFFree Cash Flow — cash left after paying for operations and capital investments; what the company can actually spend, save, or return to shareholders margin at 23.9% and returns 0.0% of its market cap via buybacks (Peer Benchmarking). Recent results show a growth acceleration; the 28% revenue increase in Q4 2025 outpaced the TTMTTMTrailing Twelve Months — the most recent full year of financial data, updated on a rolling basis each quarter growth of 21.2%, fueled by a 28% jump in OPZELURA sales (8-K). However, elevated short interest of 7.8% of the float suggests that a segment of the market remains bearish, likely focusing on the 2028 revenue gap rather than the current double-digit growth (Supplemental Signals).
4. IS IT WORTH IT AT THIS PRICE?
At 11.1x Forward P/EP/EPrice-to-Earnings ratio — share price divided by annual earnings per share; how much investors pay per dollar of profit. Higher P/E = higher growth expectations, Incyte trades at a modest discount to the peer median of 14.7x (Peer Benchmarking). According to the CAPM analysis, the market is pricing in a long-term growth rate of just 0.2%. This implied growth is exceptionally low for a company currently delivering 21.2% revenue growth—the highest among its peers. The discount appears to be a direct reflection of the 2028 patent cliff and the risk of "boxed" warnings or clinical failures cited in Incyte's filings (Risks). For the current price to be "right," the market must assume that Incyte’s 14 pivotal clinical trials will largely fail to offset the eventual decline of JAKAFI (8-K).
5. WHAT WOULD CHANGE THIS VIEW?
- Constructive if Incyte receives FDA approval for JAKAFI XR or the "enFuse" on-body delivery system, which would provide a concrete mechanism to retain its patient base beyond the 2028 patent expiration.
- Cautious if the "Hematology and Oncology" net product revenue falls below the 2026 guidance range of $800 million to $880 million, signaling that Incyte is failing to diversify away from JAKAFI quickly enough (8-K).
6. BOTTOM LINE
Structural Advantage: High-efficiency medicinal chemistry and a 92.9% gross margin supported by a specialized U.S. commercial team and exclusive global collaborations. Bottom Line: Incyte is a high-performance growth engine currently sold at a discount because of a single, well-defined expiration date in 2028.
1. Top 5 Material Risks
- Dependence on JAKAFI: JAKAFI is the first product Incyte marketed in the United States and continues to contribute a significant percentage of total revenues. Incyte expects these sales to decline upon the expiration of patent exclusivity in 2028.
- Generic Competition: Multiple generic manufacturers have filed Abbreviated New Drug Applications (ANDAs) or New Drug Applications (NDAs) challenging patents covering JAKAFI and OPZELURA. An unsuccessful defense of these patents could result in the entry of generic versions, decreasing sales.
- Pricing and Reimbursement Pressure: Incyte’s ability to sell products profitably depends on coverage and reimbursement from government and private payors. Initiatives to manage drug costs, such as the U.S. 340B drug pricing program and foreign government price controls, exert downward pressure on pricing.
- Regulatory and Clinical Trial Risks: Incyte faces risks related to the failure of clinical trials, the inability to obtain regulatory approvals for new indications, and the potential for regulatory agencies to require additional studies or impose "boxed" warnings, which could negatively affect sales.
- Manufacturing and Supply Chain: Incyte relies on third-party manufacturers for most of its products. Disruptions at these facilities, or the inability to scale production, could lead to supply shortages and harm Incyte’s ability to meet demand.
2. Company-Specific Risks
- Collaborator Conflicts: Incyte depends on partners like Novartis and Eli Lilly for the development and commercialization of certain products. Disputes over milestone payments, royalties, or the interpretation of collaboration agreements could lead to costly litigation or the termination of these revenue-generating relationships.
- Acquisition Integration: Incyte pursues acquisitions to grow its pipeline, such as the 2024 acquisition of rights to tafasitamab and the acquisition of Escient Pharmaceuticals, Inc. These transactions carry risks of integration failure, unanticipated costs, and the potential for significant write-offs if acquired assets do not perform as expected.
- Geographic Expansion: As Incyte expands operations into Canada, China, and Japan, it faces risks related to conflicting international laws, foreign currency exchange rate fluctuations, and the complexity of managing diverse government payor systems.
- Concentration of Operations: Most of Incyte’s drug discovery, research, and development activities are conducted at its headquarters in Wilmington, Delaware. The loss of access to this facility, whether due to natural disasters or other disruptions, would interrupt Incyte’s business.
3. Regulatory/Legal Risks
- Healthcare Fraud and Abuse Laws: Incyte is subject to federal and state anti-kickback laws and the False Claims Act. Alleged violations regarding promotional activities or patient assistance programs could result in significant fines, criminal penalties, or exclusion from federal healthcare programs like Medicare and Medicaid.
- Physician Payment Sunshine Provisions: Incyte must publicly report payments made to physicians and teaching hospitals. Failure to comply with these transparency requirements can lead to enforcement actions and negative publicity.
- Data Privacy Regulations: Incyte is subject to evolving global data protection laws, such as the EU’s General Data Protection Regulation (GDPR). Noncompliance can result in fines of up to €20 million or 4% of annual global revenue.
- Environmental and Safety Regulations: Incyte’s research involves hazardous and radioactive materials. Incyte faces potential liability for improper handling or disposal of these substances, which could exceed insurance coverage and total assets.
4. Financial Impact Map
- Dependence on JAKAFI → Total Revenues → Significant percentage of total revenue derived from JAKAFI; expected decline starting 2028.
- Generic Competition → Product Sales → Potential for decreased sales volume and pricing if generic versions enter the market.
- Pricing and Reimbursement Pressure → Net Product Revenues → Increased gross-to-net deductions due to rebates, discounts, and formulary exclusions.
- Regulatory and Clinical Trial Risks → Research and Development Expenses → Increased costs from mandated confirmatory trials or additional studies required by the FDA.
- Acquisition Integration → Operating Results → Potential for significant write-offs and impairment charges if acquired businesses or assets fail to meet revenue expectations.
Recent Filings
| Form | Filed | Period |
|---|---|---|
| 8-K | Feb 2026 | — |
| 10-K | Feb 2026 | Dec 2025 |
| 10-Q | Oct 2025 | Sep 2025 |
| 14A | Apr 2025 | — |
AI-extracted key facts from press releases and SEC filings. Significance 1–10.
Incyte Q4 Revenue $1.51B +27.8% YoY, Beats Estimates by 11.4%
- ▸Incyte Q4 revenue $1.51B, +27.8% YoY, beat estimates by 11.4%
- ▸Incyte reported significant miss on analyst EPS estimates
- ▸Novavax Q4 revenue $147.1M, +66.6% YoY, beat estimates by 57.4%
- ▸United Therapeutics Q4 revenue $790.2M, +7.4% YoY, missed estimates by 2.5%
- ▸Biotech sector Q4 revenues beat consensus estimates by 6.8% on average
Incyte Q4 Revenue $1.5B Beats Estimates, EPS $1.80 Misses Consensus
- ▸Q4 revenue $1.5B, exceeding Wall Street forecast of $1.4B
- ▸Q4 adjusted EPS $1.80, missing analyst expectations of $1.94
- ▸Shares declined 8% following Q4 earnings report on Feb 10
- ▸Stock up 54% over past 52 weeks, outperforming Dow Jones
- ▸Consensus rating 'Moderate Buy' with mean price target of $109.59
Incyte Targets $3B-$4B Core Revenue by 2030, Projects 15-20% CAGR Post-Jakafi
- ▸Core business 2025 revenue $1.2B, +50% YoY growth
- ▸Projected 15%–20% five-year CAGR for non-Jakafi business
- ▸Four product launches planned over next 12–18 months
- ▸Povorcitinib approval expected by late 2026 or early 2027
- ▸Initiating at least two Phase III studies for INCB0989 this year
Incyte Zynyz receives European Commission approval for advanced anal cancer treatment
- ▸European Commission approved Zynyz for first-line advanced squamous cell anal carcinoma
- ▸Approval supported by Phase 3 POD1UM-303/InterAACT2 progression-free survival data
- ▸Zynyz represents second European indication for Incyte's immuno-oncology portfolio
- ▸FDA issued Complete Response Letter for Zynyz in NSCLC on March 6
- ▸Company targets $5.9B revenue and $1.5B earnings by 2028
Incyte Q4 Revenue $1.51B Beats Estimates, EPS $1.80 Misses Consensus
- ▸Q4 revenue $1.51B, +28% YoY, beating $1.35B estimate
- ▸Q4 adjusted EPS $1.80, missing $1.94 estimate due to higher expenses
- ▸Jakafi sales $828.2M, +7% YoY, exceeding $800M estimate
- ▸Opzelura sales $207.3M, +28% YoY, beating $195.9M estimate
- ▸Niktimvo sales $56M, +22% sequentially following Q1 2025 launch